路演预告 | 海外创新项目来袭,瀚海武清生命科学云路演周五与您不见不散!

发表时间:2022-10-26 12:31


图片



“2022年度瀚海BioTalk生命科学路演会”第8场(总第26场)将于北京时间2022年10月28日上午9点30准时举办。

本期活动由瀚海硅谷中心、武清开发区高村科技创新园、瀚海瀚海武清国际创新中心共同主办,我们精选5个海外医疗创新项目,现诚邀机构、行业伙伴、创业者们拨冗参会,共同推动生命科学创新发展。


►►►

项目介绍

1

利用机器学习和蛋白质标的化研发基因疗法


Crosshair公司利用人工智能及其特有的靶向技术,设计了一套全新的RNA编码治疗方案,与最新的免疫疗法相比,实现了精准靶向的创新。该项目首先专注肿瘤、长寿和神经退行性疾病等尚且难以用药的领域:

全世界每年有2000万新增癌症病例,预计到2030年,仅癌症市场的价值就将达到274亿美元,而该项目的新技术可以治疗目前尚未攻克的癌症,使公司能够在肿瘤治疗市场脱颖而出。

预计到2030年,长寿市场将扩大至9000亿美元,而Crosshair在这市场有能力领先其竞争对手。

依靠Crosshair的高效传递系统,它的神经退行性疾病治疗方案使其能够在这个130亿美元市场占有一席之地。

基于抗体的治疗虽然精确,但很难将其传递到细胞内的靶点,而该公司的技术则可以到达目标靶点,利用RNA在工程化腺相关病毒载体(AAV)内进行,该载体保护有效物质,并确保不脱靶,有效避免了副作用和临床试验失败。公司主要候选对象可以在几周内完成设计,几个月内获得临床前概念验证,这将提交IND的时间从5-6年缩短到18个月。

图片


Crosshair Therapeutics harnesses artificial intelligence and a proprietary targeting technology to design an entirely new class of RNA-encoded therapeutics, achieving a step change in precision targeting compared to the latest immunotherapies. For our initial focus, we have chosen hard-to-drug targets in oncology, longevity, and neurodegenerative disease.

Each year, there are 20 million new cases of cancer worldwide. The cancer market alone is projected to be worth $274BB by 2030, and Crosshair has a novel technology to access previously undruggable cancer targets enabling the company to make a significant impact in this market area. The longevity market is expected to expand to $90BB by 2030. Our platform has the ability to access those targets unreachable to date by our competitors. Our neurodegenerative programs will benefit from our unique payload delivery system, allowing us to take a share of this $130BB market.

Unlike antibody-based therapies, which while precise, are difficult to deliver to targets inside the cell, our technology can access both external and internal targets. Our therapies are delivered as RNA inside an engineered adeno-associated viral vector (AAV) that protects the payload and ensures no off-targeting, a major cause of adverse side effects and clinical trial failure. Our lead candidates can be designed within weeks and pre-clinical proof-of-concept gained within a few months, which cuts our timeline to IND submission to 18 months instead of 5-6 years.


2

人工智能超声检测技术


在超声成像专业医疗领域发展50年后,当前这一技术即将步入大众消费市场,使得用户可以在家里、药店等场景中进行超声检测。

PONS的AI驱动移动超声技术将允许消费者在没有任何医学背景的情况下对自己进行超声检查。该系统能够对检查部位自动进行风险评估和智能图像处理,并向医生报告医学图像。


图片

Fifty years after its first introduction into the professional medical domain, ultrasound imaging is now ready to enter the consumer market space so that ultrasound can be used at home, in pharmacies, or by mobile Medicare teams.

PONS`s AI-driven mobile Ultrasound technology will allow consumer without any medical background for performing medical imaging of their conditions. The system autonomously carries out the risk assessment of tissues, smart image processing, segmentation, and reporting of medical images to the doctor.


3

云端数位驱动健康平台

Sensifree致力于创新医院血压监测技术,以降低术后并发症和死亡率。每50名成年人接受非心脏手术中会有1人会在术后30天内死亡,心血管并发症是主要致死原因。最新研究表明,手术期间出现低血压会提高术后不久发生心血管并发症风险,这主要是因为血压主要利用袖带监测,而袖带所提供的间歇性读数会遗漏很多数据。虽然可以利用有创动脉线进行连续监测,然而这一设备系统复杂,非必要不使用。

Sensifree正在努力创造一个连续、无创的监测平台,弥补袖带和有创动脉线之间的监测能力差距,该平台非常易于使用,已获CE认证。该解决方案使用指尖PPG(光学)传感器作为其信号源,使用方便,操作成本低。公司目前正在开发该平台,以覆盖更多适应症,主要用于普通病房的患者早期预警,以在潜在患者病情恶化之前发出警报,以及远程患者监控。

Sensifree还开发了该产品的OEM版本,用于集成患者监护仪,并已与亚洲企业合作,通过向医院销售显示器、一次性传感器和OEM产品等方式盈利。公司资金运转良好,毛利率大于80%。

Sensifree正在建立完善的全球知识产权组合,并未来市场预估达数十亿美元。目前需求150万美元的融资,以进行商业化,产品开发、营销活动和发展战略伙伴。

图片

Sensifree is innovating blood pressure monitoring in hospitals, initially targeting post-surgery complications and mortality. One out of 50 adults undergoing a non-cardiac surgery dies within 30 days of the operation. The main reason for this is cardiovascular complications. Recent studies have shown that episodes of low blood pressure during surgery increase the probability for cardiovascular complications shortly after that. Here is the problem - blood pressure is mostly monitored using a cuff, providing intermittent readings that misses many of these events. There is an option for continuous monitoring, with invasive arterial line, but it comes with a whole set of complexities and is used only when absolutely necessary. We are bridging over this gap in monitoring capabilities between the cuff and the invasive arterial line with a continuous, non-invasive monitoring platform that is very easy to use and is already CE certified. The solution uses a fingertip PPG (optical) sensor as its signal source, offering ease of use and low operating costs. We are currently developing the platform to cover additional indications, primarily for patient Early Warning use in the general ward, to alert ahead of potential patient deterioration. Additional applications include remote patient monitoring. We have also developed an OEM version of the product, for integration in patient monitors and already working with an Asian manufacturer of patient monitors. Revenue come from selling monitors and disposable sensors to hospitals, as well as OEM products. Unit economic is solid, with gross margin > 80%. We are building a strong IP portfolio - multinational filing, owned by the company, and projecting a multi billion-dollar market. We are raising a $1.5M bridge round, followed by a B-round to go commercial, continue product development, marketing activities and development of strategic partnerships.


4

实时检测状态的可穿戴贴片

Senseer Health(“Senseer”)成立于2017年,深耕迅速发展的慢性病市场,通过开发智能医疗设备治疗来管理一系列慢性病。Senseer的解决方案包括两个互补的产品线,MultiSense和SenseerCare。

MultiSense由微传感器组成,最初由南加州大学开发,并受到六项已颁发专利的保护,利用可植入设备远程监测肾脏、心血管疾病、脑积水患者的状态。

SenseerCare是一款创新的远程患者监控解决方案,结合可穿戴和环境传感器技术,监控和管理全身健康和慢性疾病,如痴呆、高血压和COPD。

这两个产品线正与物联网软件平台集成,形成专有数据库,并实现预测分析,以得到一个全面的解决方案,及时进行干预,以缓解日益恶化的慢性病,从而降低治疗成本,让患者安心,提高生活质量。

由于老龄化人口的显著增加,全球慢性病管理治疗和设备技术市场预计将从2021的3920亿美元增至2026年的5530亿美元,其中75%的老年人至少患有一种慢性病。因此,Senseer最初的目标是养老行业。

除美国外,Senseer正在与一家总部位于上海的风投讨论成立合资企业,合资企业将支持SenseerCare的最终开发,并将这两个产品线在大中华区商业化。由于中国是世界上最大的老龄化和慢性病市场,因此养老行业创新是潜力巨大。

Senseer的团队在神经科学、生物医学工程、医疗设备研发、人工智能、养老和创业成长方面拥有丰富的经验,主要投资者是总部位于香港的幸福资本(Happiness Capital)。公司正在筹集400万美元资金中剩余的150万美元,以完成SenseerCare在美国和中国的开发并开始商业化,并加速向FDA提交MultiSense 510(K)。


图片

We are Med tech solution that in conjunction with approved medical devices offer early-stage detection of hypertension and remote patient monitoring of a hypertension condition at worksites, offices, etc.

Our algorithm can detect after 6 blood pressure measurements a change in the normal ranges of blood pressure measurements and trigger a connection via digital channels (sms, email or whatsapp) we then engage with the patient within a digital program where we provide with a teleconsultation with a doctor who will diagnose and recommend the best treatment and prescription, also we will provide with nutritional and mental health support to control the disease.

We then continue to monitor for changes in those identified patients in a convenient and easy manner, by just checking their measurements at the work place, our AI would identify any changes positives or negatives and trigger more appointments if need to change dose or just a regular follow up.

We are solving the detection of hypertension do to the fact that blue-collar workers commute long times and generally family doctors and hospital have long wait hours. we offer a simple, accessible and convenient way to tackle chronic conditions.


5

自动化健康筛检

Cardiotrack致力于开发Med-tech解决方案,利用经批准的医疗设备在工厂、办公室等地提供高血压早期检测和远程患者监测服务。

项目算法可以在6次血压测量后检测到血压测量正常范围的变化,并通过短信、电子邮件或whatsapp等渠道送达患者,并在应用软件中与患者进行互动。在这一应用中,项目与医生进行远程会诊——医生将诊断并推荐最佳治疗方案和处方,公司还将提供营养和心理健康支持,以控制疾病,并在之后继续以便捷方式监测患者变化。只需在工作场所检查他们的测量结果,该项目的人工智能将识别出任何或坏或好的变化,并在需要改变方案或定期随访时获得更多用户。

Cardiotrack正在创新高血压检测方案来应对工人通勤时间长,家庭医生和医院的等待时间长造成的不便,以一种简单快捷的方法治疗慢性病。

图片


We are Med tech solution that in conjunction with approved medical devices offer early-stage detection of hypertension and remote patient monitoring of a hypertension condition at

We are Med tech solution that in conjunction with approved medical devices offer early-stage detection of hypertension and remote patient monitoring of a hypertension condition at worksites, offices, etc.

Our algorithm can detect after 6 blood pressure measurements a change in the normal ranges of blood pressure measurements and trigger a connection via digital channels (sms, email or whatsapp) we then engage with the patient within a digital program where we provide with a teleconsultation with a doctor who will diagnose and recommend the best treatment and prescription, also we will provide with nutritional and mental health support to control the disease.

We then continue to monitor for changes in those identified patients in a convenient and easy manner, by just checking their measurements at the work place, our AI would identify any changes positives or negatives and trigger more appointments if need to change dose or just a regular follow up.

We are solving the detection of hypertension do to the fact that blue-collar workers commute long times and generally family doctors and hospital have long wait hours. we offer a simple, accessible and convenient way to tackle chronic conditions.




关于M7

M7全球生物医药创新加速器位于美国硅谷,我们重点聚焦生命科学前沿技术创新,协同外部创新战略伙伴,利用M7全球化网络资源以及专业服务能力,推动北美地区医药创新生态圈的建设,赋能最具潜力的创新型初创企业更快实现商业成功。

M7生命科学加速器拥有丰富的导师资源——我们联合美国医生联盟组织(GHIN)、美国精准医疗协会(AAPM)、瀚海北美生物医药资本(Hanhai Biolabs) 以及世界投资者峰会(WISE),建立了由70余名导师和讲师组成的专家导师库,其中一半以上是临床医疗专家,加速器资源网络遍布全球多个国家。

加速器通过洞察企业在商业实践中的关键需求,为其提供项目成长过程中的多个关键资源——涵盖优化商业模式、资本运作指导、市场开发与拓展、合作伙伴对接、国际化发展、运营管理提升、实验室与办公空间等多方面专业指导及对接服务。同时入选企业将加入M7全球优质创新网络,与美国临床医疗专家联盟、全球企业合作伙伴、知名基金及投资人建立密切合作伙伴关系,并更好的连接大企业资源。


关于我们


图片


瀚海武清国际创新中心旨在整合瀚海集团创新创业服务、资源、项目、人才、团队辐射量的优势,依托瀚海五家国家级孵化器和美加德三个国家八家海外园区的资源,为武清区本地中小企业展现全新的国际化孵化加速平台,进一步打通武清区与 北京、美国、加拿大、德国之间的“高速通道”,同时围绕武清区以大数据为支撑的智慧产业,催化北京和武清区之间的企业转化、加速和产业化,助力武清区经济转型升级,为京津走廊地区的智慧产业加速孵化、科技交流与人才合作提供支撑与保障。




图片


关于我们      |      产品中心      |      新闻动态      |      客户案例      |      联系我们     
国际孵化
跨境加速
产城融合
合作共赢
INTErRNATIONAl INCUBATION
CROSS BORDER ACCELERATION

INTEGRATION OF PRODUCTION AND CITY

WIN-WIN COOPERATION